Internal Selection Competitions

Christopher and Dana Reeve Foundation Quality of Life Grants – COVID-19: Addressing Social Isolation Grants (WUSTL Key Required) Internal Selection deadline is 02/11/2021 (OPEN); Applications due to Foundation 03/15/2021

DOS Counter Misinformation and Disinformation about COVID-19 (US Mission to Poland) (WUSTL Key required) Internal Selection deadline is 02/01/2021 (OPEN); Application due to DOS 02/28/2021

Internal Opportunities

Identifying and addressing the challenges of COVID-19 through artificial intelligence, technology, and big data (McDonnell International Scholars Academy and Social Policy Institute (SPI))

  • Deadline is February 26, 2021
  • The McDonnell International Scholars Academy and the Social Policy Institute (SPI) at Washington University in St. Louis are seeking proposals from Washington University researchers and international partners that identify and address the challenges of COVID-19 through artificial intelligence, technology, and big data. This is the second year the Social Policy Institute and McDonnell Academy have partnered to provide seed grants for international research. SPI’s focus on cross-sector collaboration and international research is a natural complement to the McDonnell Academy’s emphasis on incubating domestic and international research talent and strengthening Washington University’s global profile. As such, this joint seed grant program will capitalize on the strengths of both institutions and further establish Washington University as a leader in global research.
  • Funding provided in part by the Mastercard Impact Fund, in collaboration with Mastercard Center for Inclusive Growth.
  • The McDonnell Academy’s network of premier partner universities can help to facilitate joint research. Proposed projects are encouraged to include an international collaborator from any of the McDonnell Academy’s partner universities, and can include other institutions as well. Preference will be given to projects that also foster collaborations across disciplines.
  • Seed grants are available to support faculty research responsive to this call. We anticipate funding up to three proposals at $25,000 each.

Opportunities for Current NIH Funded Researchers (Competitive Revisions & Supplements)

See examples of NIH Administrative Supplements in Box (WUSTL Key required)

Reminder – Requesting Extensions for Early Career Scientists Whose Career Trajectories Have been Significantly Impacted by COVID-19 (NOT-OD-21-052)

Release Date: February 2, 2021

  • The COVID-19 pandemic, along with extensive mitigation measures, has adversely affected progress in many biomedical research settings. Evidence from multiple sources, including a survey NIH issued to its extramural research workforce, indicates legitimate concerns about career trajectory for early career scientists. Therefore, within existing constraints of available funding, NIH plans to support early career scientists whose career trajectories have been significantly affected by the pandemic.
  • Therefore, NIH is providing an opportunity for recipients of NIH Fellowship (“F”) and NIH Career Development (“K”) awards who have been impacted by COVID-19 to request extensions as follows:
  • No-Cost ExtensionsFor most NIH awards, recipients may extend the final budget period of the previously approved project period (e.g. no-cost extension) one time, without NIH prior approval. For Fellowships and some career development awards (e.g., K99), the first no-cost extension may be submitted by the Authorized Organization Official (AOR) as a prior approval request to the funding IC(s). Recipients may also submit prior approval requests for second no-cost extensions. These requests must include a justification outlining the impact of COVID-19 on the recipient’s training and career development activities and will be considered by the funding IC(s) on a case by case basis.

Notice of Special Interest: Administrative Supplements for the Clinical and Translational Science Award (CTSA) Program to Address COVID-19 Public Health Needs (NOT-TR-21-017)

First Available Due Date is January 28, 2021; Expiration Date is August 17, 2024

  • The National Center for Advancing Translational Sciences (NCATS) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for projects that address the COVID-19 Public Health Emergency. The Clinical and Translational Science Award (CTSA) Program is uniquely qualified to contribute to these efforts.
  • NCATS expects to issue 1-4 awards for involvement with clinical studies and trials in support of COVID interventions, as well as providing clinical samples and assessing infectious or convalescent status.

Notice of Special Interest: Administrative Supplement Opportunity to Study the Impact of COVID-19 on Global Cancer Prevention and Control (NOT-CA-21-033)

  • This Notice of Special Interest (NOSI) informs current awardees that the National Cancer Institute (NCI) is providing the opportunity for supplemental funding to stimulate interest and promote studies on the impact of the COVID-19 pandemic on global cancer prevention and control. This Administrative Supplement is designed to support NCI-funded investigators who have existing relationships/partnerships in low- and middle-income countries (LMICs), inclusive of upper-middle-income countries, to leverage those partnerships to conduct research on the pandemic’s impact on cancer prevention, diagnosis, treatment, and outcomes.
  • Studies should contribute to understanding the impact of COVID-19 on global cancer prevention and control. This may include the direct effects of COVID-19 in cancer patients or the indirect health, economic, and sociocultural impacts of the pandemic across the cancer continuum.
  • Studies that generate an evidence base necessary to mitigate the effects of this and future pandemics on persons with cancer, at risk for cancer, undergoing treatment for cancer, or in remission are especially encouraged.

Notice of Special Interest: Administrative Supplements for COVID-19 Impacted NIMH Research

Expiration Date: June 2, 2023

  • The purpose of this Notice is to outline priorities for providing supplemental funding to investigators and institutions with active National Institute of Mental Health (NIMH) awards that have been significantly impacted by the COVID-19 pandemic.
  • In concert with the NIH priorities, the NIMH aims to prioritize supplement requests in the following order:
  • Trainees with F32, K01, K08, and K23 awards that are in the last year of the award
    • Projects where the entire investment is at-risk including
    • Human subjects studies in which completion of enrollment and follow-up are critical for project success
    • Longitudinal cohort studies
    • Principal investigators whose grants are ending with no additional funding
    • Projects where substantial components of the investment are at risk
    • Resources that support multiple projects/institutions

Limited Competition Emergency Awards: Shared Personal Protective Equipment Resources for COVID-19 Related Vaccine and Treatment Clinical Trials and Clinical Studies (S10 Clinical Trial Not Allowed) (PAR-20-256)

  • The purpose of this public health emergency funding opportunity is to provide Personal Protective Equipment (PPE) to directly support the needs of the NIAID’s vaccine and treatment clinical trials and clinical studies for COVID-19. This program will ensure that adequate protective equipment is available to directly assist in safely carrying out the clinical activities and direct interactions with the patients participating in the trial. Eligibility is limited to recipients conducting COVID-related clinical research and clinical studies supported by NIAID’s emergency appropriation provided by “The Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020” and “The Coronavirus Aid, Relief and Economic Security (CARES) Act”.
  • Applications accepted on a rolling basis.
  • NIAID intends to commit up to $25M for this initiative. Application budgets are not limited but need to reflect the actual needs of the proposed project.

Notice of Special Interest (NOSI): Simulation Modeling and Systems Science to Address Health Disparities (NOT-MD-20-025)
Expiration date is 5/8/2023; First available due date is 10/05/2020

  • Research Objectives:
    • Foster trans-disciplinary partnerships and collaborations in understanding the etiology and causal pathways of health disparities using SMSS
    • Use SMSS to identify modifiable barriers and cost-effective factors to reduce and eventually eliminate health disparities
    • Use SMSS to improve patient safety and reduce medical errors for populations affected by health disparities
    • Use SMSS to assess and predict the spread and consequences of pandemics (e.g., SARS-CoV-2) and the effectiveness of interventions in populations affected by health disparities
    • Provide evidence-based simulation or prediction of the impact of effective or ineffective health disparities interventions delivered in real-world settings
    • Promote big data harmonization and novel analytic methods in SMSS to address minority health and health disparities
  • Research Methodology
    • Examples of research methods could include but are not limited to:
    • System dynamics modeling
    • Network Analysis
    • Agent-based modeling
    • Dynamic microsimulation modeling
    • Discrete event simulation
    • Markov modeling
    • Hybrid simulation modeling (e.g., sequential design, enrichment design, integration design, and parallel design)
  • Research Topics: Applications should be relevant to the objectives of the funding opportunity announcement and to at least one of the participating institutes’ and offices’ research interests. Researchers are strongly encouraged to review the general research interests of the participating ICs.

Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Select Research Activities related to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (NOT-AI-20-059)
Notice expires on 7/2/21

  • NIAID is allowing the submission of applications for Competitive Revisions to active grants to increase and enhance select research efforts to facilitate the Federal SARS-CoV-2/COVID-19 research response. Areas of interest are limited to:
    • Support to BSL3 facilities actively engaged in the SARS-CoV-2/COVID-19 research response, e.g., equipment sharing arrangements. Applications proposing new construction, alterations and renovations for planned and active BSL3 facilities are not responsive to this NOSI;
    • Generation of critical reagents to support the SARS-CoV-2/COVID-19 research response;
    • Expansion of relevant data systems to expeditiously share SARS-CoV-2/COVID-19 research resources with the broad research community; and
    • Expansion of clinical trial infrastructure, or site preparation, for urgent SARS-CoV-2/COVID-19 clinical trial activities. Applications proposing clinical trials are not responsive to this NOSI.

Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions and Administrative Supplements for Research on Coronavirus Disease 2019 (COVID-19) in Individuals with Down Syndrome for the INCLUDE Project
Application Due Dates are 11/12/20, 3/12/21, or 7/12/21

  • This NOSI highlights the urgent need for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) in individuals with Down syndrome in conjunction with the INCLUDE (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE) Project. The overarching goal of this NOSI is to improve understanding and treatment of COVID-19 infection in individuals with Down syndrome and reduce COVID-19 associated morbidity and mortality for this population, which may be disproportionately affected by, have higher infection rates of, and/or be at elevated risk for adverse outcomes from contracting the virus.

Notice of Special Interest (NOSI): Availability of Urgent Competitive Revisions and Administrative Supplements For Research on Biological Effects of the 2019 Novel Coronavirus on the Nervous System
(NOT-NS-20-051)

Expires 4/15/21

  • NINDS is encouraging the submission of competitive revision or administrative supplement applications for supplements to address the biology, pathophysiology, prevention, diagnosis, sequelae, or treatment of the 2019 Novel Coronavirus that are directly related to the NINDS mission.

Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus and the Behavioral and Social Sciences (NOT-OD-20-097)
Applications will be accepted on a rolling basis through 3/31/21

  • OBSSR, NHLBI, NIA, NIAAA, NIDDK, NIEHS, NCCIH, NCI, and ORWH encourage submission of applications for urgent competitive revisions or administrative supplements to active grants studying existing longitudinal cohorts, particularly those cohorts with considerable data relevant to COVID-19 social and behavioral factors prior and subsequent to the SAR-CoV-2 outbreak in various locations. Submissions are encouraged to consider four areas: public health mitigation efforts; economic, social and personnel well-being; misinformation being communicated; downstream health effects from economic and social impacts.

Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Mental Health Research on the 2019 Novel Coronavirus (NOT-MH-20-047)
Applications accepted on a rolling basis until 4/15/21

  • NIMH, NIA, NIAAA, and NIMHD are accepting applications for supplements and revisions to active projects that significantly improve our understanding of the risks, mechanisms, and treatment in response to COVID-19 among individuals at risk for, or experiencing mental disorders across the full lifespan. This includes but is not limited to, individuals with Mild Cognitive Impairment (MCI), Alzheimer’s disease and Alzheimer’s disease related dementias (AD/ADRD) and their healthcare providers and caregivers.

Notice of Special Interest (NOSI): Competitive and Administrative Supplements for the Impact of COVID-19 Outbreak on Minority Health and Health Disparities (NOT-MD-20-019)
Applications accepted on a rolling basis until 5/1/21

  • NIMH, NIA, and NIMHD are accepting applications for supplements and revisions to active projects. This NOSI is soliciting research in health disparity populations that -seeks to understand: 1) how state and local policies and initiatives mitigate or exacerbate disparities in health services use and health outcomes; 2) the role that community-level protective and resilience factors and interventions have in mitigating the effects of the sector disruptions that the COVID-19 outbreak causes; and 3) how behavioral and/or biological mechanisms may contribute to COVID-19 manifestations.

Notice of Special Interest (NOSI): NIEHS Support for Understanding the Impact of Environmental Exposures on Coronavirus Disease 2019 (COVID-19) (NOT-ES-20-015 / PA-20-135)
Applications are accepted the first week of each month. See Notice for specific dates. (Notice expires on 5/4/21)

  • NIEHS is particularly interested in applications that will provide insight into the role of environmental exposures in pathogenicity, transmission, individual susceptibility, or prevention and intervention strategies. NIEHS is accepting applications addressing COVID-19 through the urgent competitive revision, and time-sensitive mechanisms (see Application Information below).

Notice of Special Interest (NOSI): NIA Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19) (NOT-AG-20-022)
Applications will be accepted on a rolling basis from April 6, 2020 through May 1, 2021

  • In order to rapidly improve our understanding and available control measures for 2019-nCoV, NIA is encouraging the submission of applications for either Administrative Supplements (PA-18-591) or Competitive Revisions (PA-18-935) to active grants to address multiple areas of interest within the mission of NIA.

NIDA Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus (NOT-DA-20-047)
Applications will be accepted on a rolling basis through 3/31/21

  • NIDA is especially interested in research collecting and examining data on the risks and outcomes for COVID-19 infection in individuals suffering from substance use disorders. Applications must be submitted using the following funding opportunities: PA-18-935, which is intended to provide funds for NIH grantees applying to expand the scope of their active grant, or PA-18-591, which is intended to provide funds for NIH grantees where the work proposed in the supplement is fully within the scope of the ongoing grant.

NIAID Notice of Special Interest (NOSI): Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (NOT-AI-20-031)
Application due dates depend on grant mechanism (Notice expires on 4/5/21)

  • National Institute of Allergy and Infectious Diseases (NIAID) is particularly interested in projects focusing on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against SARS-CoV-2/COVID-19. Applications may be submitted as administrative supplements (PA-18-591) to existing awards.

Clinical and Translational Science Awards Limited Funding Opportunities

Notice of Special Interest (NOSI): Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Heath Need
Application due dates depend on grant mechanisms

NIH Funding Opportunities (New Applications)

*NEW* Notice of Intent to Publish a Research Opportunity Announcement for RADx-UP Return to School Diagnostic Testing Approaches (OT2 Clinical Trial Required)

Release date: February 12, 2021

  • The purpose of this Notice is to alert the community that NIH plans to publish a Research Opportunity (RO) as part of the Rapid Acceleration of Diagnostics for Underserved Populations (RADx-UP) initiative to solicit research on COVID-19 diagnostic testing approaches to safely return children and staff to the in-person school setting in underserved and vulnerable communities. The RO will consist of two phases: 1) a targeted solicitation to rapidly accelerate ongoing research already in place in the school setting; 2) an open solicitation to start new cohorts or approaches to gain data related to safe return. The targeted solicitation will be by invitation only and will include programs currently in place in the school setting; applications will be accepted through early March 2021 for FY21 funding with the goal to make awards no later than April 2021. The open solicitation is expected to be published in mid-April and we will accept applications through early May 2021 for FY21 funding. The goal is to make awards by June 2021 for planned implementation in the 2021-2022 school year.
  • Awards under this funding opportunity will be issued as Other Transaction Agreements (OT2), which are not grants, contracts or cooperative agreements. Other Transactions awards will involve active NIH program management. Furthermore, the OT funding mechanism provides NIH with the flexibility to design unique collaborations with private sector entities that may not have experience with commonly used assistance mechanisms such as grants and cooperative agreements.
  • The goal of RADx-UP is to reduce COVID-19 associated morbidity and mortality disparities for those vulnerable and underserved populations that are disproportionately affected by, have the highest infection rates of, and/or are most at risk for adverse outcomes from contracting the virus. This Notice encourages researchers to leverage existing partnerships with key stakeholders to develop and implement specific, targeted approaches for school testing strategies to safely return children and staff to in-person school environments in underserved communities.

SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R03 RFA-AA-21-003) (R01 RFA-AA-21-002) (R21 RFA-AA-21-004)

Expiration Date is April 15, 2021.

  • R03 This Funding Opportunity Announcement (FOA) will support research grants to address urgent, time-sensitive research questions on the relationships between alcohol consumption and COVID-19 related outcomes and consequences. The principal area of focus is research that can improve public health in the near term by informing responses to the current COVID-19 pandemic, in view of 1) the impact of alcohol misuse on incidence and severity of COVID-19 disease or 2) the effect of the COVID-19 disease and pandemic-induced restrictions on alcohol use and alcohol use disorder (AUD). Time-sensitive applications for which standard NIH review and funding timelines would compromise either the ability to conduct the research or the value of the knowledge and with the potential to inform responses to the current pandemic will be considered. This FOA uses the R03 mechanism, which is intended to support research projects that can be carried out in a short period of time with limited resources and that may provide preliminary data to support a subsequent R01, or equivalent, application.
  • R01 This Funding Opportunity Announcement (FOA) will support research grants to address urgent, time-sensitive research questions on the relationships between alcohol consumption and COVID-19 related outcomes and consequences. The principal area of focus is research that can improve public health in the near term by informing responses to the current COVID-19 pandemic, in view of 1) the impact of alcohol misuse on incidence and severity of COVID-19 disease or 2) the effect of the COVID-19 disease and pandemic-induced restrictions on alcohol use and alcohol use disorder (AUD). Time-sensitive applications for which standard NIH review and funding timelines would compromise either the ability to conduct the research or the value of the knowledge and with the potential to inform responses to the current pandemic will be considered. Applications to this RFA should be accomplished within a three year project duration.

R21 This Funding Opportunity Announcement (FOA) will support research grants to address urgent, time-sensitive research questions on the relationships between alcohol consumption and COVID-19 related outcomes and consequences. The principal area of focus is research that can improve public health in the near term by informing responses to the current COVID-19 pandemic, in view of 1) the impact of alcohol misuse on incidence and severity of COVID-19 disease or 2) the effect of the COVID-19 disease and pandemic-induced restrictions on alcohol use and alcohol use disorder (AUD). Time-sensitive applications for which standard NIH review and funding timelines would compromise either the ability to conduct the research or the value of the knowledge and with the potential to inform responses to the current pandemic will be considered. This FOA uses the R21 grant mechanism, which is intended to support investigation of novel scientific ideas or new model systems, tools, or technologies that have the potential for significant impact on biomedical or biobehavioral research.

Notice of Special Interest: Medical Consequences of Smoking and Vaping Drugs of Abuse in Individuals with HIV and COVID-19 (NOT-DA-21-017)

First Available Due Date is May 5, 2021; Expiration Date is September 8, 2024.

  • NIDA is interested in receiving research applications focusing on individuals with HIV who smoke or vape marijuana, tobacco, cocaine and/or methamphetamine to determine the long-term effects of their use among individuals with HIV and COVID-19.
  • Research Areas:
    • The risks that smoking and/or vaping tobacco, marijuana, cocaine, and/or methamphetamine may have on acquiring the SARS-CoV2 infection in individuals with HIV.
    • The medical consequences, co-morbidity, and complications of SARS-CoV2 infection affecting cardiovascular, respiratory, renal, gastrointestinal, hematological, immunological, CNS and PNS systems in HIV individuals who smoke and/or vape tobacco, marijuana, cocaine, and/or methamphetamine.
    • Defining mechanisms by which substance use and HIV interact to increase susceptibility to severe COVID-19 affecting cardiovascular, respiratory, renal, gastrointestinal, hematological, immunological, CNS and PNS morbidity.
    • Utilization of large database- Electronic Health Records – strategies for retrospective and platform based prospective studies, cross analyses, and real-time health delivery and critical health-related decisions in emergency medicine settings.

Notice of Special Interest: Long-Term Neurocognitive Consequences of COVID-19 in Individuals Living with HIV and Substance Use Disorders (NOT-DA-21-018)

First Available Due Date is May 7, 2021; Expiration Date is September 8, 2024.

  • NIDA is interested in receiving research applications focusing on studying the long-term neurocognitive consequences of the COVID-19/HIV/SUDs syndemic.
  • This NOSI encourages, but is not limited to, research applications in the following areas:
    • Long-term neurocognitive effects of HIV/COVID-19/SUDs. Basic science studies to explore changes in neuroanatomy, neurophysiology, biochemistry, learning and behavior.
    • Clinical studies to evaluate cognitive, behavioral, neuropsychiatric, neuro-therapeutic outcomes, etc. Staging and categorizing of cognitive dysfunction. Differentiation between HAND and COVID-19 neurocognitive impairment in individuals with and without SUDs. Validation of neurocognitive scales for HAND and COVI-19 neurocognitive impairment.
    • Neurocognitive studies in individuals with HIV/COVID-19/SUDs classified by age/gender/race/socioeconomic status/drug of choice use/ART regime/HCV status/other co-morbidities/criminal justice involvement, etc.
    • Therapeutic strategies for such neurocognitive dysfunction in the context of HIV. Effectiveness of NMDA receptor antagonists, Anticholinergics, B12 supplements, Thiamine, SSRI’s, Benzodiazepines, Antipsychotics, etc., and its interactions with ART and SUDs. Cognitive Behavioral Therapy; Mindfulness; Meditation; Transcranial Magnetic Stimulation and others.

Notice of Special Interest (NOSI): NIDCR Support for Research on the Physiological Involvement of Oral Cavity in Coronavirus Disease 2019 (NOT-DE-21-001)

First Available Due Date is June 5, 2021; Expiration Date is May 8, 2023.

  • The oral/nasal route serves as the SARS-CoV-2 point of entry into the host thus playing a pivotal role in viral spread and COVID-19 onset and progression. As such, limiting viral infectivity, replication, shedding, and load at the point of entry is crucial to containing COVID-19 progression, as well as transmission to others. This NOSI will support studies focused on the role of oral/nasal cavity and oral manifestations related to SARS-CoV-2 and/or COVID-19 within the NIDCR mission. The areas of interest include:
    • Investigation of the biological underpinnings of SARS-CoV-2 infection, transmission, and progression in the oral cavity, including the microbiota oral-gut axis and its dysbiosis; effects of ACE2 expression distribution and function at oral/nasal SARS-CoV-2 point of entry; salivary glands as a reservoir for SARS-CoV-2; oral mucosal immunity, and differential interactions of SARS-CoV-2 mutants/variants with oral/nasal cells.
    • Investigation of the physiological mechanisms of oral manifestations of COVID-19, including salivary gland dysfunction in SARS-CoV-2 susceptibility; SARS-CoV-2 related causes of taste dysfunction; oral lesions; and changes in vascularization.
    • Establishment of predictive value and prognostic potential of oral manifestations of the severity of COVID-19 and post-acute sequalae of COVID-19.
    • Definition of the interactions between SARS-CoV-2 and oral/nasal microbiota and potential therapeutic roles of pre/probiotics and other exogenous modulators of these viral-bacterial interactions, as well as blockers of viral-receptor interactions that may limit infectivity of SARS-CoV-2.
    • Development of tools and technologies to facilitate studies in the focus areas of this initiative, including animal models, ex vivo models including oral/nasal tissue chip platforms, and computational modeling of virus-receptor interactions, among others.
  • Projects that overlap with or will result in incremental knowledge gained from existing investments in COVID-19 research by NIDCR or NIH initiatives such as the Rapid Acceleration of Diagnostics (RADx), are discouraged. Clinical observations and other descriptive studies without mechanistic analyses will be considered non-responsive.
  • Potential applicants are strongly encouraged to contact the Program Official to discuss responsiveness and appropriate mechanism before submission.

Notice of Special Interest (NOSI): Aging-Relevant Behavioral and Social Research on Conronavirus Disease 2019 (COVID-19) (NOT-AG-21-015)

First Available Due Date is March 4, 2021; Expiration Date is May 8, 2023.

  • NIA is issuing this Notice of Special Interest (NOSI) to highlight the continuing need for behavioral, psychological, social, and economic research on SARS-CoV-2 and coronavirus disease 2019 (COVID-19). There is a need for ongoing research on the longer-term effects of COVID-19 on the health and well-being of those infected, those caring for the sick, and many others whose lives were disrupted by the pandemic and its associated mitigation and prevention strategies. Beyond effects on individuals, this pandemic has brought about unprecedented social and economic disruption that is expected to have long-term and profound effects on the health of the population. These effects will likely be particularly acute for NIH-designated health disparity populations, and other COVID-19 vulnerable groups including older adults, who have experienced higher rates of COVID-19 infection, who in some cases rely on the efforts of paid and unpaid care partners, and who may have additional barriers to accessing the medical system itself. Further, middle-aged and older frontline healthcare and essential workers and their families face unique risks of exposure to both infection and other health-related outcomes by virtue of their employment.
  • Recommended areas of research include, but are not limited to, the following:
    • Use of longitudinal studies collecting multidisciplinary data (often from nationally representative and diverse samples) in order to elucidate how COVID-19 related changes in the social, economic, institutional, and policy environments differentially impact the health and welfare of people across the life course and in vulnerable social groups; inform programs and policies to prepare the world for the next pandemic; and compare regional and national impacts and approaches.
    • Use of longitudinal studies to gather unique “real-time” data for rapid assessments of risk factors and outcomes in order to guide evolving public health and treatment strategies.
    • Studies exploiting “natural experiments” associated with COVID-19 economic and health shocks as well as differences in local policies related to mitigation and prevention in order to assess direct and indirect impacts on health and well-being.
    • Studies focused on the challenges involved in informing vulnerable populations about preventative health measures (e.g., hand washing, mask wearing, physical distancing, vaccine uptake) and securing and maintaining broad adherence in order to slow virus spread and limit illness and deaths. For example: How do vulnerable groups and older adults more generally get their information and what sources do they trust? What factors support or discourage adherence to prevention practices and vaccine uptake? What accounts for individual, age, and group differences in adherence to prevention efforts? Do social networks serve to reinforce or disrupt prevention efforts?
    • Studies focused on how the short- and longer-term pandemic has influenced economic and social shocks (e.g. unemployment, foreclosure, loss of health insurance) affecting the health and well-being of different populations (e.g., rural/urban, older/middle age/younger, racial/ethnic groups).
    • Studies examining how physical distancing requirements and associated social isolation and loneliness impact the health and well-being of midlife and older adult populations, including impacts on psychological well-being, cognitive health, and health behaviors. What strategies implemented by individuals, health systems, institutions, communities, and local governments have been more or less successful at mitigating social isolation and loneliness among older adults?
    • Research considering how mitigation strategies and accompanying financial strain influence health care utilization and health, including individuals with disabilities, multiple chronic conditions, mild cognitive impairment, and/or Alzheimer’s disease and Alzheimer’s disease-related dementias, as well as their care partners and families. What are the interrelated health and economic implications of stay-at-home policies on the health and well-being of midlife and older adults with family care responsibilities, including care for children and older family members?
    • Evaluation of strategies used by health systems to reallocate resources, rapidly train practitioners, communicate preventative practices, and maintain adherence to public health and clinical guidelines during the COVID-19 pandemic, with a particular interest in those that serve high-risk groups (e.g., nursing homes) and resulting racial, ethnic, and/or regional disparities in access/care.
    • Studies examining the extent to which existing age, racial, ethnic, gender, socioeconomic, or geographic health disparities are exacerbated by the COVID-19 epidemic, including studies of 1) differential access to and use of health care services, and 2) differential access to information about, attitudes toward, and uptake of preventive measures, testing, and vaccines.
    • Research to address vaccine hesitancy, uptake, and implementation among NIH-designated health disparities populations and other COVID-19 vulnerable populations. For example: How do multilevel factors, including policies, health systems, communication modalities (e.g. social media), community-level factors, and interpersonal and individual-level variables reduce or maximize vaccine access, uptake, and series completion in different populations? How might programs to reduce concerns, increase trust and preparedness, and facilitate uptake of the vaccine be best implemented in various settings and environments (e.g., nursing homes, assisted living facilities, medical centers, dental clinics, community health clinics, pharmacies, Tribal health facilities, workplaces, pharmacies, remote care settings, and non-healthcare contexts)?

Notice of Special Interest (NOSI): Effects of smoking and vaping on the risk and outcome of COVID-19 infection (NOT-DA-21-011)

First Available Due date is June 5, 2021; Expiration Date is September 8, 2024.

  • The purpose of this notice is to communicate NIDA’s interest in supporting research on the effects of smoking or vaping tobacco or marijuana on the risk of acquiring COVID-19 and the clinical course of the infection. This Notice is a reissuance of NOT-DA-20-084.
  • Research Objectives: NIDA is interested in receiving research applications focusing on individuals who smoke or vape either marijuana and/or tobacco to determine: 1) the risk of contracting a COVID-19 infection, 2) the effects on asymptomatic COVID-19 infected persons, and 3) the course of the COVID-19 infection.
  • This NOSI encourages research to understand:
    • The risks that smoking or vaping tobacco or marijuana may have on acquiring the COVID-19 infection.
    • The medical consequences, co-morbidity, and complications of COVID-19 infection in individuals who smoke or vape tobacco or marijuana.

The medical consequences of COVID-19 in individuals who smoke and vape with comorbid conditions such as: SUD, HIV and other immunosuppressive diseases, mental health disorders, diabetes mellitus, obesity, cardiovascular, pulmonary, renal, and hepatic pathologies, as well as cancer.

Notice of Special Interest: Promoting Research on COVID-19 and Rheumatic, Musculoskeletal and Skin Diseases (NOT-AR-21-012)

Expiration date is November 19, 2021

  • The outbreak of COVID-19 caused by the novel SARS-CoV-2 has spread worldwide leading to large numbers of infections and deaths. A wide spectrum of clinical manifestations and outcomes, ranging from asymptomatic disease to multiorgan failure, has become a hallmark of the COVID-19 pandemic. Patients with many underlying diseases and conditions are at increased risk of acquiring and having adverse outcomes from SARS-CoV-2 infection. Furthermore, persistent symptoms (post-acute sequelae), including fatigue, muscle pain, weakness or wasting, joint pain, skin rash, arthritis, and biobehavioral changes, are being reported among COVID-19 survivors, even among individuals who initially experience a mild acute illness. As of this writing, the FDA has issued Emergency Use Authorization for two vaccines recommended to prevent COVID-19, and several other vaccines and treatments are in various stages of preclinical and clinical development. While there is no obvious indication of adverse events or impacts of the use of these vaccines in individuals with underlying rheumatic, skin, and or musculoskeletal diseases/conditions, research studies should be carried out to determine if these individuals will be affected differently by COVID-19 vaccines and treatments as compared to those without such conditions. In line with overall NIH efforts, NIAMS would like to promote basic, translational, pre-clinical and clinical observational research focused on COVID-19 infection and its intersection with rheumatic, musculoskeletal, and skin diseases and conditions.
  • This NOSI encourages, but is not limited to, research applications focused on:
  • Susceptibility to, prevalence, risk assessment, and clinical management of COVID-19 among patients with underlying rheumatic, musculoskeletal, and/or skin diseases;
  • The impacts of drugs or other targeted therapies that are used to treat diseases within the mission of NIAMS on susceptibility, severity, and management of COVID-19;
  • Health disparities and social/behavioral factors that contribute to risk of infection, organ injury and adverse outcomes in COVID-19 patients with underlying rheumatic, musculoskeletal, and/or skin diseases;
  • Impact of COVID-19 vaccination of patients with underlying rheumatic, musculoskeletal, and/or skin diseases;
  • Characterization of long-term post-acute sequelae occurring in recovered COVID-19 patients with co-existing rheumatic, musculoskeletal, and/or skin diseases;
  • Characterization of NIAMS-mission related long-term post-acute sequelae (e.g. muscle pain, joint pain, biobehavioral changes, skin rash, arthritis, etc.) occurring in recovered COVID-19 patients.

Notice of Special Interest: Effects of smoking and vaping on the risk and outcome of COVID-19 infection (NOT-DA-20-084)

Expiration date is September 8, 2024; First Available Due Date is January 4, 2021

  • The purpose of this notice is to communicate NIDA’s interest in supporting research on the effects of smoking or vaping tobacco or marijuana on the risk of acquiring COVID-19 and the clinical course of the infection.
  • Research Objectives: NIDA is interested in receiving research applications focusing on individuals who smoke or vape either marijuana and/or tobacco to determine: 1) the risk of contracting a COVID-19 infection, 2) the effects on asymptomatic COVID-19 infected persons, and 3) the course of the COVID-19 infection.
  • This NOSI encourages research to understand:
    • The risks that smoking or vaping tobacco or marijuana may have on acquiring the COVID-19 infection.               
    • The medical consequences, co-morbidity, and complications of COVID-19 infection in individuals who smoke or vape tobacco or marijuana.
    • The medical consequences of COVID-19 in individuals who smoke and vape with comorbid conditions such as: SUD, HIV and other immunosuppressive diseases, mental health disorders, diabetes mellitus, obesity, cardiovascular, pulmonary, renal, and hepatic pathologies, as well as cancer.

Notice of Special Interest: Repurposing Existing Therapeutics to Address the 2019 Novel Coronavirus Disease (COVID-19) (NOT-TR-21-006)

Expiration Date is March 17, 2021; First Available Due Date is October 30, 2020

  • National Center for Advancing Translational Sciences (NCATS) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 novel coronavirus (SARS-CoV-2) and the disease it causes, i.e., “coronavirus disease 2019” (COVID-19). NCATS is particularly interested in projects that repurpose existing drugs or biologics (existing therapeutics) that have already begun or completed a Phase I clinical trial.
  • The hypothesis for proposed studies must be developed using innovative processes to identify the therapeutic/indication pair. Examples include the following:
    • Testing a publicly posted therapeutic candidate for use to treat COVID-19. Examples include clinical candidate therapeutics in documents publicly posted by the World Health Organization (types/classes of candidate therapeutics) and (candidates for clinical evaluation).
    • Testing a candidate therapy to treat COVID-19 that was already identified with a publicly available computational approach.
    • Testing of existing therapeutic candidates that work on mechanistic targets shared among other viruses that may be relevant to SARS-CoV-2.

NCATS is soliciting applications to PAR-17-465, PAR-18-462, and PAR-18-332.

Notice of Special Interest: Research on Rehabilitation Needs Associated with the COVID-19 Pandemic (NOT-HD-20-031)

Expiration date is May 8, 2023; First Available Due Date: February 05, 2021

  • This NOSI invites research applications on the rehabilitation needs of COVID-19 survivors. At present, the best acute rehabilitation plan for people who have recovered from severe cases of COVID- 19 is unknown. Similarly, the long-term rehabilitation needs and sequalae of people who recover from COVID-19 are not well understood. Furthermore, the interplay of existing physical disabilities and recovery from COVID-19 is also unknown.
  • Research applications are also sought to understand the impact of disruptions to rehabilitation services caused by the COVID-19 pandemic and associated mitigation actions. Applications that measure the impact of delayed treatment for common disabling conditions, such as stroke, are also sought.
  • Finally, research applications investigating the social, behavioral, and economic impact of COVID-19 on people with physical disabilities and their caregivers are requested.
  • Topics of interest include but are not limited to:
    • New clinical trials of acute, chronic, home, and community-based rehabilitation interventions (types, dosing, timing, and intensity) for survivors of severe COVID-19 (e.g. with lung involvement, neurological symptoms, or muscle wasting)
    • EHR analysis of rehabilitation services associated with COVID-19 treatment
    • Physical, social, economic, and health outcomes for patients who receive COVID-19 rehabilitation
    • Studies of how pandemic containment and mitigation actions, such as social distancing requirements, affect the care and well-being of people with disabilities and their caregivers
    • Studies focused on addressing the unique needs of formal and informal caregivers in assisting/supporting survivors of COVID-19 use new methods of rehabilitation delivery during the pandemic
    • Studies of how social distancing guidelines and requirements are implemented and impact people with disabilities in institutions, group settings, and other non-traditional settings
    • Studies examining the impact of healthcare-related stigma, discrimination, harassment, and/or refusal of care on seeking COVID-related healthcare for people with disabilities
    • Development and testing of new methods for delivery of rehabilitation in the home. Target patient groups include both people requiring rehabilitation following COVID-19 as well as typical rehabilitation patients
    • Development and testing of novel metrics of function for use in the home environment with emphasis on the use of mobile or digital devices

Health Services Research on Minority Health and Health Disparities (R01 – Clinical Trial Optional) PAR-20-310

Application Due Dates: November 27, 2020; March 17, 2021; November 17, 2021; March 17, 2022; November 17 2022; February 17, 2023. Expiration Date is March 28, 2023.

  • The purpose of this Funding Opportunity Announcement (FOA) is to encourage innovative health services research that can directly and demonstrably contribute to the improvement of minority health and/or the reduction of health disparities at the health care system-level as well as within clinical settings.
  • Examples of research methods could include, but are not limited to:
    • Cluster-randomized, randomized or practical clinical trials of the effectiveness of new or existing technologies (e.g., telehealth), non-technological interventions, and multi-level interventions that involve broad inclusion of patients from health disparity populations and addresses a disease or condition that disproportionately impacts health disparity populations (e.g., infectious diseases such as COVID-19, chronic diseases such as cancer, diabetes, cardiovascular conditions, asthma, and others, mental health/substance abuse disorders including perinatal depression, and maternal and infant mortality).
  • Research topics of interest include but are not limited to:
    • Studies on the effects of emerging infectious diseases such as the COVID-19 pandemic on disparities in health care utilization and health outcomes among medically vulnerable populations such as institutionalized and non-institutionalized older adults; persons with chronic conditions, mental health and/or substance abuse disorders, complex medical needs, and/or with compromised immune system function; and pregnant women. In addition, examine the effects of these infectious diseases on disparities in health care utilization and health outcomes among socially vulnerable populations such as the homeless, the recently incarcerated, immigrants, persons with disabilities, and children.
    • Studies on the effects of the COVID-19 pandemic on disparities in access to care and quality of care for health disparity populations, taking into account how it impacts the structure and organization of different health care systems that serve health disparity populations, including those living in rural areas.
    • Research to examine the role of federal, state and local policies in different sectors (e.g., health care, labor, transportation, housing) in exacerbating or reducing the impact of the COVID-19 pandemic, chronic medical conditions, or other diseases that have disproportionate effects on minority health and health disparities.
    • Studies of clinical procedures or guidelines into existing care systems such clinician or health care system decision-making about advanced ventilatory support for patients with severe advanced COVID-19 or other acute severe diseases with high mortality.

Notice of Special Interest: Emerging Viral Infections and their Impact on the Male and Female Reproductive Tract (NOT-HD-20-021)
Expiration date is 07/16/2023; First Available due date is 10/05/2020.

  • The purpose of this Notice is to invite applications proposing cutting-edge research on emerging viral infections that are thought to primarily impact non-reproductive sites, at least at initial presentation, but may also affect the male and/or female reproductive tract. The recent global outbreak of the novel coronavirus, SARS-CoV-2, is not an anomaly and will most likely not be the last virus occurrence. Today, infectious diseases are emerging and reemerging more quickly than ever before. In the last four-five years alone, two viral infections, one caused by the Zika virus (ZIKV) and the other caused by a SARS-CoV-2 (Covid19), have spread world-wide, resulting in death, severe disease with yet, unknown, long-term morbidities., or severe birth defects to the new-born. Both ZIKV and SARS-CoV-2 infections may affect male and/or female reproductive systems in addition to other non-reproductive sites. Therefore, it becomes essential to investigate possible effects of emerging viruses on reproductive tissues and cells to better understand potential impacts on fertility that may be sex specific.
  • Currently, knowledge gaps exist in our understanding of viral infections of both male and female reproductive tract tissues. This NOSI is interested in the recently emergent ZIKA and novel corona viruses, as well as other yet unidentified viruses which may significantly impact public health. Areas of interest of this NOSI include, but are not limited to:
    • Consequences of infection, e.g., cells affected and outcomes of infection – infertility, miscarriage, live births, orchitis, epididymitis, pelvic pain;
    • Mechanism of action for infectivity of reproductive tract tissues;
    • Mechanism of sexual transmission;
    • Whether the reproductive tract acts as a reservoir for viruses;
    • Sex-specific differences in infection as they may relate to reproductive tract tissues and cells;
    • The impact of race and ethnicity on reproductive system impacts of viruses;
    • Impact of nutrition, e.g., Vitamin D sufficiency and the understanding of mechanisms that explain the impact of obesity;
    • Development of model systems to study infections in reproductive tract tissues, e.g., organoids (for R21 applications only)
  • Non-responsive applications:
    • Infections exclusively localized to the reproductive tract, e.g., urinary tract infections, chlamydia, HPV, HSV, hepatitis B;
    • Epidemiological analysis of a particular infection.

Notice of Special Interest (NOSI): Availability of Emergency Awards for Limited Clinical Trials to Evaluate Therapeutic and Vaccine Candidates Against SARS-CoV-2
Expiration date is 9/1/2021; First Available due date is 9/01/2020

  • This Notice of Special Interest encourages cooperative agreement applications for implementation of investigator-initiated high-risk clinical trials, as defined by NIAID in PAR-18-633 and NOT-AI-16-084, that will augment ongoing and planned clinical trials of therapeutic and vaccine candidates directed against SARS-CoV-2 to evaluate:
    • SARS-CoV-2 candidate vaccines
    • non-vaccine biomedical prevention of SARS-CoV-2 infection and/or COVID-19
    • therapeutic approaches to treat COVID-19
  • Please note, studies evaluating behavioral interventions (e.g., impact of face masks, hand- washing, social distancing) and those focused on disinfecting surfaces and equipment are not responsive and will not be considered for this NOSI initiative.
  • Investigators interested in responding to this NOSI are strongly encouraged to submit a written request for prior consultation to the email address listed below prior to submission of an NIAID Clinical Trial Implementation (U01) Cooperative Agreement application in response to PAR-18-633 to discuss the proposed project in the context of the needs identified above. This request should be as succinct as possible and include the study title and a brief description of the study and product to be evaluated; study PI; primary institution and potential collaborating sites; industry partners, if applicable; and a cost estimate. As a reminder, per NIH policy, applicants requesting $500,000 or more in direct costs in any year (excluding consortium F&A) must contact NIAID staff listed below no later than 6 weeks before submission and follow the Policy on the Acceptance for Review of Unsolicited Applications that Request $500,000 or More in Direct Costs as described in the SF424 (R&R) Application Guide.

Intervention Research to Improve Native American Health (R01 Clinical Trial Optional) (PAR-20-238)
Application due dates: May 17, 2021, May 17, 2022, May 17, 2023

  • The purpose of this funding opportunity announcement (FOA) is to support research on interventions to improve health in Native American (NA) populations. This includes 1) etiologic research, where there is a significant gap in knowledge, that will directly inform intervention development or adaptations, 2) research that develops, adapts, or tests the efficacy or effectiveness of health promotion and disease prevention interventions, 3) research that tests culturally informed treatment or recovery interventions and 4) where a sufficient body of knowledge on intervention efficacy exists, research on dissemination and implementation that develops and tests strategies to overcome barriers to the adoption, integration, scale-up, and sustainability of effective interventions. Existing data suggest that significant acute and chronic disease inequities exist for NA populations.  Concurrently, NA populations experience unique sociopolitical, historical, and environmental stressors and risks that may exacerbate health conditions and/or impact the effectiveness of existing solutions to address the conditions. They also possess unique strengths and resiliencies that can mitigate stressors or inform intervention strategies. Through this initiative, intervention and related research is sought to build upon community knowledge, resources, and resilience to test science-based, culturally appropriate solutions to reduce morbidity and mortality through identification and remediation of precursors to diseases and disorders and through culturally informed treatment.  Interventions should be designed with a consideration for sustainability within the communities where they are tested, and have the flexibility to be readily adapted, disseminated, and scaled up to other communities where culturally appropriate. For the purposes of this FOA, Native Americans include the following populations: Alaska Natives, American Indians (whose ancestral lands fall at least partially within the U.S. mainland border), and Native Hawaiians.  The term ‘Native Hawaiian’ means any individual any of whose ancestors were natives, prior to 1778, of the area which now comprises the State of Hawaii.
  • NHLBI: One of the Examples of projects of interest to NHLBI include the following: Strategies and behavioral interventions that may mitigate the impact of COVID-19 on heart, lung, blood, and sleep diseases and disorders

Notice of Special Interest (NOSI): Comprehensive Care for Adults with Type 2 Diabetes Mellitus from Health Disparity Populations (NOT-MD-20-026)
First Available Due date 10/5/20; Notice expires on 5/8/21

  • The purpose of this Notice of Special Interest is to support multidisciplinary, investigative and collaborative research focused on developing and testing multi-level strategies to effectively implement recommended guidelines of comprehensive clinical care for individuals with Type 2 diabetes from health disparity populations.
    • One example of potential topic areas mentions COVID-19
      • Studies on the multi-level effects of the COVID-19 pandemic and/or their intersection on access to health care services and continuity of care, for example patient level factors (e.g., loss of health insurance due to job loss; impact on self-management due to caregiving and homeschooling responsibilities) health care setting level factors (e.g., changes and rescheduling of services due to policies on physical distancing; medication availability and refills, health care settings strategies and best practices to ensure appropriate and timely care), and societal factors (impact of policies on physical distancing on nutrition, physical activity, and emotional well-being). Costs/economic analyses are of interest.

Urgent Phase I/II Clinical Trials to Repurpose Existing Therapeutic Agents to Treat COVID-19 Sequelae (U01)
Applications will be accepted on a rolling basis, beginning on 8/6/2020

  • The purpose of this urgent funding opportunity announcement is to invite applications to repurpose existing therapeutic agents to treat Coronavirus Disease 2019 (COVID-19) sequelae and associated complications that result from Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infections. The therapeutic agent must have already completed at least a Phase I clinical trial for a different indication, and not require additional regulatory studies for the new indication prior to starting a clinical trial.

Notice of Intent to Publish a Funding Opportunity Announcement for HEALthy Brain and Child Development Study (NOT-DA-20-069)

  • NIH plans to publish a set of Funding Opportunity Announcements (FOAs) as part of the Helping to End Addiction Long-termSM (HEAL) Initiative to support research project sites, a Data Coordinating Center, and a Consortium Administrative Core for the HEALthy Brain and Child Development (HBCD) Study. The primary objective of the HBCD Project is to conduct a large scale multi-site longitudinal study that can prospectively examine human brain, cognitive, behavioral, social, and emotional development beginning at birth and extending through middle childhood. The FOAs are expected to be published in Fall 2020 with an expected application due date in WINTER 2021.

Mechanistic Studies of the Interaction between SARS-CoV-2/COVID-19 and Diseases and Organ Systems of Interest to NIDDK (R01 Clinical Trial Optional, RFA-DK-20-021)
Applications are due 12/16/20

  • This FOA support basic and clinical mechanistic research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) susceptibility, routes of infection, course of disease, morbidity and mortality in people with pre-existing diseases, or adverse acute or chronic outcomes in organs, tissues, and biological systems of specific interest to NIDDK. 

Digital Healthcare Interventions to Address the Secondary Health Effects Related to Social, Behavioral, and Economic Impact of COVID-19 (R01 – Clinical Trial Optional)
Applications are due 12/2/20, or 3/2/21

  • Focuses on the role and impact of digital health interventions [e.g., mobile health (mhealth), telemedicine and telehealth, health information technology (IT), and wearable devices] to address access, reach, delivery, effectiveness, scalability and sustainability of health assessments and interventions for secondary effects (e.g., behavioral health or self-management of chronic conditions) that are utilized during and following the pandemic, particularly in populations who experience health disparities and vulnerable populations

Notice of Special Interest (NOSI): Utilizing Telemedicine or Other Remote-Based Platforms to Develop and Support Treatments for Substance Use Disorders
This notice applies to standard R01 and R21 due dates on or after October 5, 2020 and subsequent due dates until 1/8/24.

  • We expect this NOSI to accelerate the development of 1) remotely-delivered SUD treatment interventions, and 2) remote methods for collecting outcome measures evaluating the safety or efficacy of SUD treatments. These advances will facilitate the delivery of effective treatments to those in need and permit the execution of clinical trials when physical access to clinical research sites is limited. Ultimately, both these advances will lead to improved treatment options for individuals with SUD.

NIA Multi-site COVID-19 Related Clinical Trial Implementation Grant on Aging-Related Topics in at-risk Older Adult Populations (R01 Clinical Trial Required)
Applications are due: 11/2/2020, 11/2/,2020, 12/1/2020, 1/4/2021, 2/1/2021

  • Invites applications for implementation of investigator-initiated multi-site clinical trials (all phases or stages) of interventions focused on specific aging-related issues to reducing transmission, risk, morbidity, mortality, severity, or complications of Coronavirus Disease 2019 (COVID-19)


NIA Multi-site COVID-19 Related Clinical Trial Implementation Grant on Aging-Related Topics in at-risk Older Adult Populations (R01 Clinical Trial Required)
Applications are due November 2, 2020; December 1, 2020; January 4, 2021; and February 1, 2021.

  • This Funding Opportunity Announcement (FOA) invites applications for implementation of investigator-initiated multi-site clinical trials (all phases or stages) of interventions focused on specific aging-related issues to reducing transmission, risk, morbidity, mortality, severity, or complications of Coronavirus Disease 2019 (COVID-19). 

Notice of Special Interest (NOSI): NIDCD is Interested in Supporting Research on the Impact of COVID-19 on Mission Specific Sensory and Communication Disorders
This notice applies to due dates on or after October 5, 2020 and subsequent receipt dates through September 8, 2022.

  • NIDCD invites applications for research on COVID-19 in relation to NIDCD’s scientific programs of hearing, balance, taste, smell, voice, speech and language (HBTSVSL). Given the early stage of COVID-19 research, it is critical that there is a strong premise for research proposals submitted in response to this NOSI. When appropriate, NIDCD encourages multi-disciplinary approaches to move the research beyond in vitro and animal models.

New COVID-19 priority areas and due dates for PAR-19-373 and PAR-19-384, “Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery (R01)”
Next application due date: 3/17/21

  • These FOAs solicits research projects that seek to model the underlying mechanisms, processes, and trajectories of social relationships and how these factors affect outcomes in health, illness, recovery, and overall wellbeing. There are new priority topics related to COVID-19 pandemic.

RadX – Tech – NIH POCTRN Fast-Track Program for COVID-19 Test Development and Distribution Innovative Technologies to Increase U.S. Capacity for COVID-19 Testing
Accepting proposals for support on a rolling basis until further notice

  • NIBIB is urgently soliciting proposals and can provide up to $500M across multiple projects to rapidly produce innovative SARS-CoV-2 diagnostic tests that will assist the public’s safe return to normal activities.

Long-Term Effects of Disasters on Health Care Systems Serving Health Disparity Populations (R01- Clinical Trial Optional) (PA-20-172)
Standard due dates starting 10/5/20

  • This FOA supports investigative and collaborative research focused on understanding the long-term effects of natural and/or human-made disasters, such as the COVID-19 pandemic, on health care systems serving health disparity populations in communities in the U.S.

Mechanism for Time-Sensitive Research Opportunities in Environmental Health Sciences (R21 Clinical Trial Not Allowed) (RFA-ES-19-011 / NOT-ES-20-015)
Applications are accepted the first week of each month. See Notice for specific dates. (Notice expires on 5/4/21)

  • NIEHS is particularly interested in applications that will provide insight into the role of environmental exposures in pathogenicity, transmission, individual susceptibility, or prevention and intervention strategies. NIEHS is accepting applications addressing COVID-19 through the urgent competitive revision, and time-sensitive mechanisms (see Application Information below).

Notice of Special Interest (NOSI): Availability of Emergency Competitive Revision and Administrative Supplements on Biomedical Technologies for Coronavirus Disease 2019 (COVID-19) (NOT-EB-20-007)
Application standard due dates apply (Notice expires on 3/31/21)

  • The NIBIB is seeking new R01, R21, and R03 applications to develop life-saving technologies that can be ready for commercialization within one to two years.

Notice of Special Interest (NOSI): Small Business Research and Development of Biomedical Technologies for Coronavirus Disease 2019 (COVID-19) (NOT-EB-20-006)
Standard application due dates apply (Notice expires on 3/31/21)

NIAID Notice of Special Interest (NOSI): Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (NOT-AI-20-031)
Application due dates depend on grant mechanism (Notice expires on 4/5/21)

  • National Institute of Allergy and Infectious Diseases (NIAID) is particularly interested in projects focusing on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against SARS-CoV-2/COVID-19. Applications may be submitted through R03, R21, or R01 mechanisms.

NSF Funding Opportunities & Priorities

Smart and Connected Communities (S&CC) (NSF 21-535)
Full Proposal Deadline is February 24, 2021

  • Communities in the United States (US) and around the world are entering a new era of transformation in which residents and their surrounding environments are increasingly connected through rapidly-changing intelligent technologies. This transformation offers great promise for improved wellbeing and prosperity but poses significant challenges at the complex intersection of technology and society. The goal of the NSF Smart and Connected Communities (S&CC) program solicitation is to accelerate the creation of the scientific and engineering foundations that will enable smart and connected communities to bring about new levels of economic opportunity and growth, safety and security, health and wellness, accessibility and inclusivity, and overall quality of life.
  • For the purposes of this solicitation, communities are defined as having geographically-delineated boundaries—such as towns, cities, counties, neighborhoods, community districts, rural areas, and tribal regions—consisting of various populations, with the structure and ability to engage in meaningful ways with proposed research activities. A “smart and connected community” is, in turn, defined as a community that synergistically integrates intelligent technologies with the natural and built environments, including infrastructure, to improve the social, economic, and environmental well-being of those who live, work, learn, or travel within it.
  • S&CC Integrative Research Grants (SCC-IRG) Tracks 1 and 2. Awards in this category will support fundamental integrative research that addresses technological and social science dimensions of smart and connected communities and pilots solutions together with communities. Track 1 proposals may request budgets ranging between $1,500,001 and $2,500,000, with durations of up to four years. Track 2 proposals may request budgets up to $1,500,000, with durations of up to three years. Note that NSF is working with the Japan Science and Technology Agency (JST) to support joint US-Japan IRG Track 2 proposals (SCC-IRG JST) that address topics related to recovery from COVID-19 and future resilience planning related to pandemics and disasters, including how the proposed research will enable community adjustment to life in the new normal of a post-COVID-19 society.

Joint NSF-BSF Programs Dealing with the Coronavirus Disease
Applications may be submitted anytime

  • The U.S.-Israel Binational Science Foundation (BSF) is accepting applications dealing with the Coronavirus Disease in all the active NSF-BSF programs. Applications must be written jointly by an Israeli scientist in an Israeli institution and a U.S. scientist from a U.S. research institution. Proposals should be submitted through the NSF Rapid Response Research (RAPID) funding mechanism. Presently, all biology units of the NSF (BIO), Geosciences, Materials, Physics and CBET divisions are open for submission.

NSF Dear Colleague Letter on the Coronavirus Disease 2019 (COVID-19) (NSF 20-052)
Applications may be submitted anytime

  • NSF is accepting proposals to conduct non-medical, non-clinical-care research that can be used immediately to explore how to model and understand the spread of COVID-19, to inform and educate about the science of virus transmission and prevention, and to encourage the development of processes and actions to address this global challenge.

Centers for Disease Control and Prevention

Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation’s Health (RFA-OT18-18020301SUPP21)

Deadline for submission of Application is March 5, 2021

  • The purpose of this notice of funding opportunity (NOFO) is to announce the availability of supplemental funding for the organizations that were previously awarded funding under Funding Strategy 1 of CDC-RFA-OT18-1802: Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation’s Health. This supplemental funding opportunity will support recipients in delivering capacity-building assistance (CBA) activities to address ongoing needs for the COVID-19 response. The CDC-RFA-OT18-1802 recipients are eligible to submit applications for COVID-19 CIO Project Plans that match the Target Population Category (A, B, or C) and Target Population Description for which they received initial funding in FY18. The COVID-19 CIO Project Plans will be attached to the NOFO once published.
  • Estimated Total Program Funding is $750,000; Award Ceiling is $250,000

Department of Energy/Private Sector

COVID-19 High Performance Computing (HPC) Consortium Request for Proposals
Applications may be submitted anytime

  • The COVID-19 High Performance Computing Consortium is a unique private-public effort to bring together federal government, industry, and academic leaders who are volunteering free compute time and resources on their world-class machines. Researchers are invited to submit COVID-19 related research proposals to the consortium, which will then be reviewed for matching with computing resources from one of the partner institutions.

Department of State

Counter misinformation and disinformation about COVID-19 (WUSTL Key Required) Internal Selection deadline is 02/01/2021 (OPEN); Application due to DOS 02/28/2021. Award ceiling is $20,000

  • The U.S. Embassy and Consulate in Poland are pleased to announce a Notice of Funding Opportunity (NOFO) for grants of up to $20,000 for projects beginning no earlier than April 2021. The deadline for this NOFO, #WAW-NOFO-FY21-01, is Sunday, February 28, 2021. PROJECT THEMES: This call is for proposals for innovative projects that:
    • Counter misinformation and disinformation about COVID-19, including, but not limited to, information campaigns, social media campaigns, science workshops for journalists, educational activities for students, etc.
    • Counter misinformation and disinformation about the COVID-19 vaccine, including, but not limited to, information campaigns, social media campaigns, training for journalists about the science behind vaccines, educational activities for students, etc.
    • Teach high school and/or university students to think critically about information they see on social media about the COVID-19 pandemic and vaccine, including examining sources, evaluating multiple points of view, and considering the agendas of information sources.
    • Equip educators to teach students to think critically about information they see on social media about the COVID-19 pandemic and vaccine, including examining sources, evaluating multiple points of view, and considering the agendas of information sources.

**Please note: Applications that do not specifically address one of the four topics above will be disqualified.**

ELIGIBILITY:

  • Grants will be awarded to local representatives of Polish non-governmental organizations, cultural or educational institutions, media, and individuals whose proposals support the topics listed below.
  • All grantees must have a non-profit status.
  • One application per organization or individual. Organizations which currently have an open grant from the Embassy should not apply.
  • NGOs and individuals from the United States may apply, but should present evidence of a relationship with a local partner operating in Poland in their proposals.
  • In order to receive a grant, all organizations (not individuals) must have a DUNS number and a valid SAM.gov registration (registrations are valid for one year). Instructions are in Section F.

NASA

Making Innovative Use of NASA Satellite Data to Address Environmental, Economic, and/or Societal Impacts of the COVID-19 pandemic
Applications will be accepted on a rolling basis through 3/29/21

  • NASA’s Earth Science Division (ESD) would like to call the attention of the Earth Science research, applications, and data systems communities to Program Element A.28 “Rapid Response and Novel Research in Earth Science” (RRNES) of Research Opportunities in Space and Earth Sciences (ROSES) 2020 as an opportunity to propose investigations making innovative use of NASA satellite data to address regional-to-global environmental, economic, and/or societal impacts of the COVID-19 pandemic.

NIST

NIST Manufacturing USA National Emergency Assistance Program (2020-NIST-MFGUSA-NEAP-01)
Applications will be accepted on rolling basis
(Washington University is not eligible as the lead institution but may participate on an application.)

  • National Institute of Standards and Technology (NIST) invites Manufacturing USA institutes to propose high-impact projects designed to respond to the COVID-19 pandemic.  Projects may include medical countermeasures; non-medical countermeasures; leveraging institute capabilities to strengthen state and community resilience; grants to companies and technical support to accelerate productions of critical materials, equipment, and supplies; creation of additional production facilities; technology roadmapping for pandemic response and recovery; reshoring the manufacture of critical conventional drugs and ensuring supply chain for critical materials related to pandemic response; or workforce development and training for a skilled advanced manufacturing workforce.

USAID

COVID-19 FUNDING REQUESTS AND UNSOLICITED PROPOSALS
Concepts accepted on a rolling basis

  • USAID is responding to the COVID-19 pandemic with decisive action at home and abroad. Our priorities in the COVID-19 response are to protect the safety and health security of our global workforce, ensure that we can continue our life-saving mission across the world, and support partner countries in their response to COVID-19. Partners may submit unsolicited proposals to COVID19_Concepts@usaid.gov.

Non-Federal Opportunities

Longer Life Foundation Call for Applications: Developmental Research Awards – Letters of Intent are due by Midnight of February 19, 2021. Call for Applications  

  • An interactive session with Dr. Dominic Reeds, Director of the Longer Life Center, and Dr. Dan Zimmerman, Managing Director of the Longer Life Foundation, will be held on Wednesday, January 27, 2021 from 9:00 – 10:00 AM via Zoom.  Registration is required (register here). This Q&A session is offered to provide feedback on potential ideas for award applications, as well as technical details about the grant application and review processes.
  • The Longer Life Foundation’s mission is to fund and support the study of factors that either predict the mortality and morbidity of selected populations or influence improvements in longevity, health, and wellness.
  • These grants are specifically for either junior investigators who are interested in longevity-related research and have yet to obtain independent funding, or for established investigators who are developing a new direction in research on determinants of health and longevity. These awards provide up to $50,000 direct costs per year for up to 2 years to support these missions. Further, hands-on mentorship to assist scientific development is provided to junior faculty who are beginning their research careers. These grants have proven highly effective at generating pilot data for junior investigators and in allowing them to successfully compete for funding from national agencies. Please note: in the updated RFP, the project ideas have been expanded to include a few COVID-related topics.
    • Pandemic risk modeling and ways of mitigating catastrophic outcomes
    • Long-term impact of COVID-19 on mortality and morbidity outcomes

Christopher and Dana Reeve Foundation Quality of Life Grants – COVID-19: Addressing Social Isolation Grants (WUSTL Key Required) Internal Selection deadline is 02/11/2021 (OPEN); Applications due to Foundation 03/15/2021

  • The aim of the Reeve Foundation’s new grants program is to address social isolation during the COVID-19 pandemic with the goal of enhancing connectedness of people living with paralysis and their caregivers to their communities and preventing adverse health outcomes. Though they are looking to the field for innovative ways to address the program’s aim and goals, funds may support programs and projects to:
    • Connect isolated individuals and remotely foster engagement and connection through
    • Virtual support groups
    • Online activities to help support self-care and stress management
    • Virtual and online adaptive physical activity and health promotion programs
    • Art sessions
    • Gaming
  • Adapt services or create new services to continue to support and engage family caregivers
  • Facilitate connection through the use of technology, including
    • Increasing access to internet, broadband service, and tablets (via loan closets)
  • Provide programs with online opportunities for volunteering (Volunteering has been shown to have many positive health benefits)
  • Create strategies to strengthen and/or build social networks
  • Provide access to tools and resources to help people remain connected and engaged

Pfizer COVID-19 Vaccine Patient Education: Addressing Vaccine Hesitancy

  • Grant Application deadline is 02/10/2021. The total available budget related to this RFP is $500,000 USD; the expected approximate range of grant awards: $10,000 to $100,000 USD. Pfizer will consider larger grants depending on the size and scope of the program, but smaller grants for local and regional programs are a priority.
  • Through this RFP it is our intent to support patient education programs designed to increase the understanding and familiarity with COVID-19 and COVID-19 vaccination among the general population. Of particular interest are educational programs that focus on reaching the medically underserved and other under-immunized populations including those in both rural and urban settings.
  • All activity types will be considered, though given the current circumstances, virtual and digital activities will be prioritized. This includes applications to repurpose existing educational resources into easy-to-use and easy-to-access delivery formats (e.g. mobile apps.) We will also consider applications repurposing education or training resources that currently exist in one language but could be modified and translated to other languages and rolled out in different geographies.
  • It is not our intent to support clinical research projects. Projects evaluating the efficacy of therapeutic or diagnostic agents will not be considered.

Wellcome, Bill & Melinda Gates Foundation, and Mastercard
The Bill & Melinda Gates Foundation, Wellcome, and Mastercard have committed up to $125 million in seed funding to speed-up the response to the COVID-19 epidemic by identifying, assessing, developing, and scaling-up treatments. The COVID-19 Therapeutics Accelerator will play a catalytic role by accelerating and evaluating new and repurposed drugs and biologics to treat patients with COVID-19 in the immediate term, and other viral pathogens in the longer-term.

Topics: The Accelerator is seeking partners for the following activities:

  • Identifying candidate compounds by testing approved drugs for activity against COVID-19, screening libraries of compounds with confirmed safety data, and considering new investigational compounds and monoclonal antibodies.
  • Developing drugs or monoclonal antibodies that pass initial screening.
  • Scaling up production and commercialization of successful drugs and monoclonal antibodies.

PCORI Phased Large Awards in Comparative Effectiveness Research (PLACER)
LOI applications are due 9/29/2020. Full applications are due 1/12/2021.

  • This PCORI funding announcement invites applications for high-quality comparative effectiveness research (CER) projects that will examine a critical patient-centered research question that is also relevant to decision makers and other stakeholders. For this PFA, investigators should propose an individual-level or cluster randomized controlled trial of significant scale and scope, requiring funding in excess of $10 million in direct costs. The proposed trials should address important decisional dilemmas that require important new evidence about the comparative effectiveness of available interventions.

CISCO Pandemic/COVID19 Science, Technology and Social Impact

  • Cisco is interested in both the science and technology aspects of these problem sets, and, particularly, in the intersections between them. By cultivating stronger partnerships between scientists, technologists, and the broader community; we hope to achieve an acceleration of scientific research and conservation outcomes as we push the boundaries of our technologies and architectures to support larger-scale studies, more sophisticated analyses, and translation of learnings across multiple domain areas.

COVID-19 Early Treatment Fund (CETF)
Applications are accepted on a rolling basis

  • CETF is raising funds to test the most promising existing drugs in outpatient trials and helping those studies recruit patients. We are the only organization in the world that is exclusively focused on outpatient trials testing treatments immediately after infection. A scientist can apply for funding and get up to a $1M commitment in less than a week. Funding multiple shots on goal quickly is the fastest way to end the pandemic.

Robert Wood Johnson Foundation (RWJF): Pioneering Ideas – Exploring the Future to Build a Culture of Health
Proposals will be accepted on a rolling basis throughout the year

  • Pioneering Ideas: Exploring the Future to Build a Culture of Health seeks proposals that are primed to influence health equity in the future. The Foundation is interested in ideas that address any of these four areas of focus: Future of Evidence; Future of Social Interaction; Future of Food; Future of Work. RWJF welcomes proposals from scientists, anthropologists, artists, urban planners, and community leaders – anyone, anywhere who has a cutting edge idea that could alter the trajectory of health and increase opportunities for everyone in the United States to live their healthiest life possible.
  • While this RFP is focused on broader and longer-term societal trends and shifts that were evolving prior to the COVID-19 outbreak, the Foundation recognizes the unique circumstances and learning created by the COVID-19 pandemic may inform your response. It is at your discretion whether you propose a project related to the pandemic directly or indirectly.

Mozilla Open Source Support Program (MOSS) COVID-19 Solutions Fund
Applications are accepted on a rolling basis

  • Mozilla will provide awards of up to $50,000 each to open source technology projects which are responding to the COVID-19 pandemic in some way. As part of the COVID-19 Solutions Fund, we will accept applications that are hardware (e.g., an open source ventilator), software (e.g., a platform that connects hospitals with people who have 3D printers who can print parts for that open source ventilator), as well as software that solves for secondary effects of COVID-19 (e.g., a browser plugin that combats COVID related misinformation).

FastGrants – Fast Funding for COVID-19 Science
Applications accepted on a rolling basis – current on hold due to large number of application received.

  • Science funding mechanisms are too slow in normal times and may be much too slow during the COVID-19 pandemic. Fast Grants are an effort to correct this. If you are a scientist at an academic institution currently working on a COVID-19 related project and in need of funding, we invite you to apply for a Fast Grant. Fast Grants are $10k to $500k and decisions are made in under 48 hours. If we approve the grant, you’ll receive payment as quickly as your university can receive it

PCORI Funding Opportunity for COVID-19-Related Enhancements to Existing PCORI-Funded Research
Applications accepted on a rolling basis

  • PCORI seeks investigator-initiated proposals to address the COVID-19 public health crisis through enhancements of currently funded PCORI research awards. Only PCORI-funded principal investigators with active research project funding contracts are eligible to submit a proposal in response to this announcement.

Wellcome Trust – Epidemic Preparedness: COVID-19 Funding Call
Applications accepted on rolling basis

  • Applicants must be able to swiftly begin to investigate new approaches for preventing and controlling COVID-19. Proposals should focus on helping low- and middle-income countries prepare for and deal with the epidemic. Eligible applicants are researchers with a PhD or the equivalent, and significant postdoctoral research experience. These awards are open to individuals or teams of up to five members. Applicants can be based anywhere in the world (apart from mainland China). Wellcome Trust particularly encourages applications from lead applicants based in low- and middle-income countries.

Relevant Links

Additional COVID-19 Funding Opportunities

SPIN COVID-19 Links

Webinar: Proposal Writing in the Time of COVID-19 Recording and Slides from June 11, 2020.

COVID-19 & Social Determinants of Health Working Group

  • Lead by Karen Joynt Maddox, MD, MPH, co-director of the Center for Health Economics and Policy, the Institute for Public Health’s COVID-19 and Social Determinants of Health Working Group convenes regional researchers, practitioners and public health workers interested in discussing research, data, and opportunities for collaboration.
  • According to Dr. Joynt Maddox, the goals of the group are to “connect people across the university around this important topic to enable novel collaborations and help create meaningful change in clinical care and policy.”

Visualization of COVID-19 Data Using R

  • A week of virtual presentations and workshops around all things data, presented by Bernard Becker Medical Library, Washington University Libraries and the Institute for Informatics.
  • Friday, February 12, 2021 (10 AM to Noon)
  • Register